BACKGROUND: Laparoscopic mini-gastric bypass (LMGB) is an alternative to the laparoscopic Roux-en-Y gastric bypass (LRYGB), which is considered to be the gold standard in the treatment of morbid obesity. OBJECTIVES: Present 5-year results of 175 patients who had undergone a LMGB between October 2006 and October 2008. SETTING: University public hospital, France. METHODS: Complete follow-up was available in 126 of 175 patients (72%) who had LMGB. Mortality, morbidity, weight loss, co-morbidities, and quality of life were assessed. Weight loss was determined as a change in body mass index (BMI) and percent excess BMI loss (%EBMIL). Quality of life in the treatment group was analyzed using the Gastrointestinal Quality of Life Index (GIQLI) and was compared with a retrospectively case matched preoperative control group. RESULTS: There were no deaths. Thirteen patients (10.3%) developed major complications. Marginal ulcers occurred in 4% of patients. Incapacitating biliary reflux developed in 2 (1.6%) who required conversion into RYGB. Gastric pouch dilation occurred in 4 patients (3.2%) and inadequate weight loss with severe malnutrition in 2 (1.6%). At 5 years, mean BMI was 31±6 kg/m(2) and mean %EBMIL was 71.5%±26.5%. Postoperative GIQLI score of the treatment group was significantly higher than preoperative score of the control group (110.3±17.4 versus 92.5±15.9, P<.001). Social, psychological, and physical functions were increased significantly. No significant differences were found in gastroesophageal reflux or diarrhea symptoms between the 2 groups. Long-term follow-up showed an improvement in all co-morbidities. CONCLUSIONS: At 5 years, LMGB was safe, effective, and provided interesting quality of life results.
BACKGROUND: Laparoscopic mini-gastric bypass (LMGB) is an alternative to the laparoscopic Roux-en-Y gastric bypass (LRYGB), which is considered to be the gold standard in the treatment of morbid obesity. OBJECTIVES: Present 5-year results of 175 patients who had undergone a LMGB between October 2006 and October 2008. SETTING: University public hospital, France. METHODS: Complete follow-up was available in 126 of 175 patients (72%) who had LMGB. Mortality, morbidity, weight loss, co-morbidities, and quality of life were assessed. Weight loss was determined as a change in body mass index (BMI) and percent excess BMI loss (%EBMIL). Quality of life in the treatment group was analyzed using the Gastrointestinal Quality of Life Index (GIQLI) and was compared with a retrospectively case matched preoperative control group. RESULTS: There were no deaths. Thirteen patients (10.3%) developed major complications. Marginal ulcers occurred in 4% of patients. Incapacitating biliary reflux developed in 2 (1.6%) who required conversion into RYGB. Gastric pouch dilation occurred in 4 patients (3.2%) and inadequate weight loss with severe malnutrition in 2 (1.6%). At 5 years, mean BMI was 31±6 kg/m(2) and mean %EBMIL was 71.5%±26.5%. Postoperative GIQLI score of the treatment group was significantly higher than preoperative score of the control group (110.3±17.4 versus 92.5±15.9, P<.001). Social, psychological, and physical functions were increased significantly. No significant differences were found in gastroesophageal reflux or diarrhea symptoms between the 2 groups. Long-term follow-up showed an improvement in all co-morbidities. CONCLUSIONS: At 5 years, LMGB was safe, effective, and provided interesting quality of life results.
Authors: Maurizio De Luca; Giacomo Piatto; Giovanni Merola; Jacques Himpens; Jean-Marc Chevallier; Miguel-A Carbajo; Kamal Mahawar; Alberto Sartori; Nicola Clemente; Miguel Herrera; Kelvin Higa; Wendy A Brown; Scott Shikora Journal: Obes Surg Date: 2021-05-03 Impact factor: 4.129
Authors: Mario Musella; Antonio Susa; Emilio Manno; Maurizio De Luca; Francesco Greco; Marco Raffaelli; Stefano Cristiano; Marco Milone; Paolo Bianco; Antonio Vilardi; Ivana Damiano; Gianni Segato; Laura Pedretti; Piero Giustacchini; Domenico Fico; Gastone Veroux; Luigi Piazza Journal: Obes Surg Date: 2017-11 Impact factor: 4.129